Full Breakdown
Immunotherapy Shows Promise for Treatment-Resistant Depression
6/2/2026, 4:12:28 AM
Targeted Immune Approach
A double-blind randomized trial tested whether blocking interleukin-6 (IL-6) with tocilizumab could relieve symptoms in patients with treatment-resistant depression. Thirty participants with inflammation were recruited through the University of Cambridge and Cambridgeshire and Peterborough NHS Foundation Trust. Fourteen received tocilizumab; sixteen received saline placebo. Outcomes were measured over four weeks.
Scientific Rationale
Standard antidepressants target neurotransmitters, yet about one-third of patients do not improve. Elevated cytokines, especially IL-6, have been observed in a subset, suggesting an inflammatory contribution. Prior Mendelian randomization linked IL-6 genetic variants to depression risk.
Lead Investigators and Funding
Lead investigators were Professor Golam Khandakar (Psychiatry & Immunology, MRC Integrative Epidemiology Unit and NIHR BRC: Bristol) and Dr Éimear Foley (Senior Research Associate, Immunopsychiatry, MRC IEU). Funding: Wellcome; NIHR BRCs (Bristol, Cambridge); BMA Foundation J Moulton grant.
Trial Design and Primary Outcomes
Fourteen participants received tocilizumab and sixteen received placebo. Remission was 54 % in the treatment group versus 31 % in placebo, giving a number needed to treat (NNT) of 5. The tocilizumab group showed greater reductions in depression severity, fatigue, and anxiety, though the small sample limited statistical significance.
Clinical Implications
If replicated, IL-6 blockade could provide a biologically targeted option for patients whose depression is linked to inflammation, offering a lower NNT than standard SSRIs.
Official Statements & Responses
The investigators called the trial a milestone for treatments of difficult-to-treat depression and noted it is the first randomized test of IL-6 receptor inhibition for this condition. They stressed the need for a larger phase III trial to obtain efficacy data.
Criticism & Opposition
The authors acknowledged the modest sample size limited statistical power and that the four-week follow-up may miss longer-term effects.
Conflicting Reports & Gaps
The trial did not assess durability of response beyond four weeks, nor identify optimal dosing or predictive biomarkers, leaving efficacy uncertain.
On-the-Ground-Reports
Participants reported noticeable improvements in mood, energy, and daily functioning during the four-week period.
Direct Voices from the Study
> “This work represents an important milestone in the development of new treatments for depression especially difficult-to-treat depression, which affects millions of people in the UK alone.” — Golam Khandakar, Professor of Psychiatry and Immunology
> “Depression is estimated to affect around 10-20 % of people worldwide during their lifetime, yet for many patients current treatments do not work well enough.” — Dr Éimear Foley, Senior Research Associate
> “Our study moves us closer to more tailored depression care, where treatments are chosen to better fit a person’s biology. This will help us to provide the right treatment to the right patients at the right time.” — Dr Éimear Foley
> “I was happy to take part. Without research, advancements in medicine cannot be made.” — Study participant
Future Directions
A large phase III randomized trial, funded by Wellcome, NIHR BRCs (Bristol, Cambridge) and the BMA Foundation J Moulton grant, will evaluate tocilizumab’s efficacy and safety for depression.
